Johnson & Johnson (JNJ) Financials
Key financial figures for Johnson & Johnson (Q2 2027).
JNJ reported Q2 2026 sales of $25.31 billion (+6.6% reported, +5.6% operational) and adjusted EPS of $2.90, then raised full-year 2026 guidance to an estimated $101.1 billion in reported sales and $11.68 in adjusted EPS. Reported worldwide sales of $25.31B, up 6.6% year over year (operational growth 5.6%); GAAP diluted EPS was $2.27 (down 0.9% YoY) while adjusted diluted EPS rose 4.7% to $2.90, beating the prior quarter's $2.70. Innovative Medicine grew to $16.38B (+7.8% reported, +6.8% operational), led by Darzalex, Carvykti, Tecvayli, and Rybrevant/Lazcluze in oncology and Tremfya in immunology; Stelara biosimilar erosion remained a roughly 760 basis point drag. On the outlook: FY2026 estimated reported sales raised to $100.8B-$101.4B (midpoint $101.1B, +7.3% YoY); adjusted EPS raised by $0.13 to $11.60-$11.75 (midpoint $11.68, +8.2% YoY). Prior (April 2026) guide was $100.3B-$101.3B revenue (midpoint $100.8B) and $11.45-$11.65 adjusted EPS (midpoint $11.55). Figures are for Q2 2026, as Johnson & Johnson reported them.
- Revenue
- $25.3B
- Net Income
- $5.5B
- EPS
- $2.30
- Total Assets
- $201.1B
- Operating Cash Flow
- $4.7B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $25.3B | $5.5B | $2.27 | 28.34% | $3.4B |
| Q1 FY2026 | $24.1B | $5.2B | $2.14 | 26.58% | $1.5B |
| Q4 FY2025 | $24.6B | $5.1B | $2.10 | 22.76% | $5.5B |
| Q3 FY2025 | $24.0B | $5.2B | $2.12 | 29.58% | $8.4B |
| Q2 FY2025 | $23.7B | $5.5B | $2.29 | 28.68% | $2.5B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $94.2B | $26.8B | $11.03 | 27.17% | $19.7B |
| FY2024 | $88.8B | $14.1B | $5.79 | 24.94% | $19.8B |
| FY2023 | $85.2B | $35.2B | $13.72 | 27.49% | $18.2B |
Frequently asked questions
What was Johnson & Johnson's revenue last quarter?
Johnson & Johnson reported revenue of $25.31 billion for Q2 FY2026, up 6.6% from the same period a year earlier.
Is Johnson & Johnson profitable?
Yes. Johnson & Johnson reported net income of $5.53 billion for Q2 FY2026, a net margin of 21.86% on revenue.
How has Johnson & Johnson's margin trended?
Operating margin was 28.34% in Q2 FY2026, compared with 28.68% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
When does Johnson & Johnson report next?
Johnson & Johnson is scheduled to report results on 2026-10-13. The company has confirmed that date.
Full income statement, balance sheet and cash flow for Johnson & Johnson on SentiSense, with up to forty quarters and twenty fiscal years of history.